Overview

• Biopharmaceutical firm's Q4 product sales reached $114.4 mln

• Company's 2025 revenue reaches $407.3 mln

• Net loss for 2025 widened to $61.6 mln from $39.1 mln in 2024

Outlook

• Ardelyx expects 2026 IBSRELA revenue to be between $410 and $430 mln

• Company anticipates 2026 XPHOZAH revenue between $110 and $120 mln

Result Drivers

• IBSRELA GROWTH - Revenue for IBSRELA grew 73% in 2025 to $274.2 mln, driven by increased prescribing and patient engagement

• XPHOZAH DISPENSES - XPHOZAH revenue reached $103.6 mln in 2025, reflecting growth in total dispenses, including non-Medicare patients

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Ardelyx Inc is $14.00, about 108.3% above its February 18 closing price of $6.72

• The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 92 three months ago

Press Release: ID:nGNX11lgdZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)